

## CORRESPONDENCE

# Same-day treatment following point-of-care sexually transmitted infection testing in different healthcare settings in South Africa

Mandisa M. Mdingi,<sup>1</sup> Remco P.H. Peters,<sup>1-3</sup> Ranjana Gigi,<sup>1,4,5</sup> Chibuzor Babalola,<sup>6</sup> Christopher M. Taylor,<sup>7</sup> Christina A. Muzny,<sup>8</sup> Nicola Low,<sup>4</sup> Andrew Medina-Marino,<sup>9,10</sup> Jeffrey D. Klausner<sup>6</sup>

<sup>1</sup>Research Unit, Foundation for Professional Development, East London, South Africa;

<sup>2</sup>Department of Medical Microbiology, University of Pretoria, Pretoria, South Africa; <sup>3</sup>Division

of Medical Microbiology, University of Cape Town, Cape Town, South Africa; <sup>4</sup>Institute of

Social and Preventive Medicine, University of Bern, Switzerland; <sup>5</sup>Graduate School for Health

Sciences, University of Bern, Switzerland; <sup>6</sup>Department of Population and Public Health

Sciences University of Southern California ; <sup>7</sup>Department of Microbiology, Immunology &

Parasitology, Louisiana State University Health Sciences Center, New Orleans, USA; <sup>8</sup>Division

of Infectious Diseases, University of Alabama at Birmingham, Birmingham, USA; <sup>9</sup>Department

of Psychiatry, Perelman School of medicine, University of Pennsylvania, Pennsylvania, USA;

<sup>10</sup>Desmond Tutu Health Foundation, Cape Town, South Africa

Dear Editor –

We would like to congratulate Asare et al [1] on their analysis of the outcomes of point-of-care (POC) testing for sexually transmitted infections (STIs) among women in South Africa during an HIV vaccine trial. They found that, in one clinic, 92% of women with a positive test result for

---

**Contact information:** Corresponding author Prof RPH Peters, Foundation for Professional Development, Research Unit, 16 Surrey Road, East London, 5247, South Africa remcop@foundation.co.za

Alternate corresponding author MM Mdingi, Foundation for Professional Development, Research Unit, 16 Surrey Road, East London, 5247, South Africa mandisam@foundation.co.za

© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ([https://academic.oup.com/journals/pages/open\\_access/funder\\_policies/chorus/standard\\_publication\\_model](https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model))

*Chlamydia trachomatis* or *Neisseria gonorrhoeae* (Xpert® CT/NG, Cepheid, Sunnydale, California) received same-day treatment. We would like to highlight the variability in receipt of same-day STI treatment at primary healthcare (PHC) settings in South Africa.

We evaluated same-day STI treatment at the baseline visit in our ongoing implementation-effectiveness trial of STI diagnostic strategies in pregnancy in the Buffalo City Metropolitan Municipality in South Africa [2]. At four PHC clinics, we enrolled pregnant women attending their first antenatal care visit at <27 weeks of gestation. On-site testing with the Xpert® CT/NG and TV (*Trichomonas vaginalis*) assays is conducted in two of three study arms; results are usually available within 90 minutes of sampling. Women are encouraged to wait for their results and those who cannot wait are contacted by telephone. The study is approved by the Human Research Ethics Committee at the University of Cape Town (REF: 676/2019).

We have enrolled 511 women in this analysis with a median age of 28 years (interquartile range 24-32). HIV and syphilis prevalence are 29% and 2%, respectively. Overall baseline STI prevalence is 24% (125/511) with 83 women (16%) testing positive for *C. trachomatis*, 27 for *N. gonorrhoeae* (5%), and 31 for *T. vaginalis* (9%). In our cohort, 39% (49/125) of women diagnosed with an STI received same-day treatment. However, there was a large difference between the four clinics: 96% of women (26/27) received same-day treatment at one facility compared with 7/25 (28%), 7/39 (18%), and 9/34 (26%) at the others. At these clinics, 66% (66/98) received treatment within 7 days of testing (**Table 1**).

We agree that rapid STI diagnostics could improve STI management in settings where syndromic management is standard of care. The benefits of on-site STI testing, however, may depend on the setting and on test characteristics. We achieved >90% same-day STI treatment at one clinic (Facility A), which has a designated waiting area. However, most women did not wait for their results at three other PHC clinics, which are crowded and do not have a designated waiting area. Nevertheless, most women received STI treatment within 7 days following telephone follow-up. This is faster than reported by Asare et al. for laboratory-based testing (8% treated within 7 days) but similar for clinic-based testing (98% treated within 7 days). Additionally, Asare et al. used an antigen test for *T. vaginalis* that gives results in 10-15 minutes, which might contribute to the high levels of same-day treatment in clinic-based testing.

In conclusion, our findings confirm that on-site STI testing can achieve high levels of same-day treatment, but further implementation research is needed to determine the settings, populations, contexts, and test characteristics that are needed to optimize same-day STI treatment at the PHC level.

## NOTES

**Financial support.** This research was supported by the National Institutes of Health (NIH) under award 5R01AI149339-02 to A.M.-M and J.K. (also reported by C.M.T., C.A.M., and M.M.M. and R.P.H.P. (paid to institution)) and through Swiss National Science Foundation project number 197831 (reported by R.P.H.P. and N.L. (paid to institution) and R.M.S.G. as an MD-PhD scholarship (paid to institution)).

**Potential conflicts of interest.** The authors received a donation of STI GeneXpert® tests from Cepheid (California). C.A.M. declares grants or contracts from NIH/NIAID (R21AI167754-01 and R01AI146065-01A1), CDC/HHS/NCHHSTP (NU62PS924587 ), Gilead (GS-US-528-9023), Abbott (Protocol No. E239479959-21-007), and Lupin for an Investigator Initiated Trial. C.A.M. also reports consulting fees paid to them from Abbott, Visby, and Cepheid. C.A.M. reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Visby, Scynexis, and Cepheid (paid to author), participation on Scientific Advisory Boards for BioNTech, Abbott, and Scynexis (paid to author), service as a Scientific Reviewer for DynaMed (paid to author), and a has a U.S. patent currently pending (No: 63/355,887).

No other authors report conflicts of interest.

## References

- Asare K, Andine T, Naicker N, et al. Impact of point-of-care testing on the management of sexually transmitted infections in South Africa: Evidence from the HVTN702 HIV vaccine trial. Clin Infect Dis **2022**;ciac824. doi:10.1093/cid/ciac824.
- Medina-Marino A, Cleary S, Muzny CA, et al. Sexually transmitted infection to prevent adverse birth and newborn outcomes: study protocol for a randomized-controlled hybrid-effectiveness trial. Trials **2022**; 23:441.

**Table 1. Time to treatment initiation following point-of-care STI testing at four primary healthcare facilities in South Africa**

	<b>Facility A</b> <b>(N = 27)</b> <b>n (%)</b>	<b>Facility B</b> <b>(N = 39)</b> <b>n (%)</b>	<b>Facility C</b> <b>(N = 34)</b> <b>n (%)</b>	<b>Facility D</b> <b>(N = 25)</b> <b>n (%)</b>	<b>Total</b> <b>(N = 125)</b>
Same-day treatment	26 (96)	7 (18)	9 (26)	7 (28)	49 (39)
Treatment 1-7 days	0	19 (49)	13 (38)	11 (44)	43 (34)
Treatment >7 days	0	10 (26)	7 (21)	4 (16)	21 (16)
Did not return	1 (4)	3 (8)	5 (15)	3(12)	12 (10)

Abbreviations: STI, sexually transmitted infection.